We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Tomosynthesis in the Oslo Breast Cancer Screening Program (DBT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01248546
Recruitment Status : Unknown
Verified February 2013 by Per Skaane, Oslo University Hospital.
Recruitment status was:  Active, not recruiting
First Posted : November 25, 2010
Last Update Posted : February 5, 2013
Cancer Registry of Norway
Hologic, Inc.
Information provided by (Responsible Party):
Per Skaane, Oslo University Hospital

November 24, 2010
November 25, 2010
February 5, 2013
November 2010
December 2012   (Final data collection date for primary outcome measure)
Screening performance indicators [ Time Frame: From Nov. 22, 2010 to Dec. 31, 2012 ]
Not Provided
Complete list of historical versions of study NCT01248546 on ClinicalTrials.gov Archive Site
Interval cancer rate [ Time Frame: From Nov. 23, 2010 to Dec. 31, 2014 ]
Not Provided
Not Provided
Not Provided
Tomosynthesis in the Oslo Breast Cancer Screening Program
Digital Breast Tomosynthesis in the Oslo Mammography Screening Program

The Digital Breast Tomosynthesis (DBT) in the Oslo Mammography Screening Program will include women aged 50 to 69 years invited to the population-based mammography-screening program. All women attending the screening unit will be asked if they want to attend the trial. If so, they will be informed about the project, the technique, and the additional compression and radiation dose. All mammographic examinations of women attending the trial will be independently interpreted by four radiologists. Since the trial is part of the official Norwegian Breast Cancer Screening Program (NBCSP), the interpretations will be carried out on-line into the national screening database of the NBCSP. The study will include independent reading of conventional digital (2D) mammograms, 2D plus computer-aided detection (CAD), 2D plus DBT, and synthetic 2D plus DBT. There will be a common consensus meeting for all examinations having a positive score. Recalls and diagnostic work-up will be according to daily practice at the Oslo University Hospital Ullevaal and the guidelines of the NBCSP.

Outcome measures will use performance indicators for organized screening programs, including recall rate, false positive scores, cancer detection rate, positive predictive values, and cancer characteristics for the individual readers of the trial.

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Women aged 50 to 69 years attending the national breast cancer screening program who sign an informed consent regarding participation in the trial
  • Recall Rate
  • Cancer Detection Rate
  • False Positive Rate
  • Positive Predictive Value
Procedure: Digital breast tomosynthesis
The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
Digital mammography
Intervention: Procedure: Digital breast tomosynthesis

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
September 2015
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women 50 to 69 years who have signed the informed consent

Exclusion Criteria:

  • Women with pacemaker, implants, and severely disabled
Sexes Eligible for Study: Female
50 Years to 69 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
2010/144 (REK)
Not Provided
Not Provided
Per Skaane, Oslo University Hospital
Oslo University Hospital
  • Cancer Registry of Norway
  • Hologic, Inc.
Not Provided
Oslo University Hospital
February 2013